A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer

doi:10.1016/j.jddst.2022.103922

UM > Institute of Chinese Medical Sciences

Residential College	false
Status	已發表Published
	A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer
	Wang, Yan 1; Zhang, Chen 2; Xiao, Meng 2; Ganesan, Kumar 1; Gao, Fei 2; Liu, Qingqing 1,3; Ye, Zhen 1; Sui, Yue 1,3; Zhang, Feng 1,3; Wei, Kunhua 4; Wu, Yaobin 5; Wu, Jianmin 6; Du, Bing 7; Xu, Cong 1,3; Li, Yan 2; Li, Peng8 ; Zhang, Jinming 2; Chen, Jianping 1,3
	2023-01
Source Publication	Journal of Drug Delivery Science and Technology
ISSN	1773-2247
Volume	79
Abstract	Treatment of aggressive triple-negative breast cancer (TNBC) is still challenging. Isoliquiritigenin (ISL) is a water-insoluble bioactive compound possessing high anti-TNBC capacity with less toxicity. The present study aimed to develop a safe and effective oral drug delivery system to improve the oral efficacy of ISL for TNBC therapeutics. ISL-loaded zein phosphatidylcholine hybrid nanoparticles (ISL@ZLH NPs) were constructed by a one-step solvent evaporation method. Optimization and characterization of ISL@ZLH NPs were performed. Cellular uptake in vitro and biodistribution of ZLH NPs in vivo were investigated. The pharmacokinetics of ISL@ZLH NPs in terms of ISL content in the plasma, organs, and tumor tissues were validated, and the anti-TNBC efficacy was evaluated. Encapsulation efficiency (96.75 ± 1.41%) and drug loading efficiency (6.56 ± 0.83%) were found in ISL@ZLH NPs. ISL@ZLH NPs were able to enhance the absorption of ISL in the tumor sites. Moreover, the upregulation of p27 and downregulation of EGFR and CDK4 were observed in ISL@ZLH NPs treated tumors. Collectively, oral intake of ISL@ZLH NPs would be translated into a potential clinical therapy strategy against TNBC.
Keyword	Isoliquiritigenin Zein-phosphatidylcholine Hybrid Nanoparticles Bioavailability Triple-negative Breast Cancer Safe Therapeutic Strategy
DOI	10.1016/j.jddst.2022.103922
URL	View the original
Indexed By	SCIE
Language	英語English
WOS Research Area	Pharmacology & Pharmacy
WOS Subject	Pharmacology & Pharmacy
WOS ID	WOS:000897066800001
Publisher	Editions de Sante
Scopus ID	2-s2.0-85142755370
Fulltext Access	View Full-Text via DOI View Full-Text via Web of Science View Full-Text via Scopus
Citation statistics
Document Type	Journal article
Collection	Institute of Chinese Medical Sciences
Corresponding Author	Li, Peng; Zhang, Jinming; Chen, Jianping
Affiliation	1.School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 2.School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China 3.Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, China 4.Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement, Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, China 5.Guangdong Engineering Research Center for Translation of Medical 3D Printing Application, Guangdong Provincial Key Laboratory of Medical Biomechanics, Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 51 6.School of Pharmacy, Southwest Medical University, Luzhou, China 7.College of Food Science, South China Agricultural University, Guangdong, Guangzhou, 510640, China 8.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, 999078, China
Corresponding Author Affilication	Institute of Chinese Medical Sciences
Recommended Citation GB/T 7714	Wang, Yan,Zhang, Chen,Xiao, Meng,et al. A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer[J]. Journal of Drug Delivery Science and Technology, 2023, 79.
APA	Wang, Yan., Zhang, Chen., Xiao, Meng., Ganesan, Kumar., Gao, Fei., Liu, Qingqing., Ye, Zhen., Sui, Yue., Zhang, Feng., Wei, Kunhua., Wu, Yaobin., Wu, Jianmin., Du, Bing., Xu, Cong., Li, Yan., Li, Peng., Zhang, Jinming., & Chen, Jianping (2023). A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer. Journal of Drug Delivery Science and Technology, 79.
MLA	Wang, Yan,et al."A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer".Journal of Drug Delivery Science and Technology 79(2023).

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Affiliation No.
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh